ResearcherShanghai Jiao Tong UniversityNo recent work listed

Jiali Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9135-1188; OpenAlex author ID A5100405295. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper

Papers 2

Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis. Co-author DOI 10.1016/j.bbrc.2017.01.146 ↗
The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244. Co-author DOI 10.1016/j.bbrc.2014.12.019 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Pingping Hui · 2 shared papers, 2015–2017 · strength 0.15
- Paper Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis. DOI 10.1016/j.bbrc.2017.01.146 ↗
- Paper The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244. DOI 10.1016/j.bbrc.2014.12.019 ↗
Shihao Xiang · 1 shared paper, 2017 · strength 0.09
- Paper Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis. DOI 10.1016/j.bbrc.2017.01.146 ↗
Ting Wang · 1 shared paper, 2015 · strength 0.06
- Paper The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244. DOI 10.1016/j.bbrc.2014.12.019 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.